Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)B Gerber, S Loibl, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancerR Bell, J Brown, M Parmar, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trialM Untch, H Eidtmann, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trialS Loibl, C Jackisch, A Schneeweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trialC Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)G von Minckwitz, M Rezai, P A Fasching, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trialD Rayson, T M Suter, C Jackisch, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyS Loibl, M Untch, N Burchardi, et al.
Pageof 10